Ensysce Biosciences, Inc. (ENSC)
0.4705
-0.04
(-7.93%)
USD |
NASDAQ |
Oct 23, 16:00
0.465
-0.01
(-1.17%)
After-Hours: 20:00
Ensysce Biosciences Net Income (Quarterly) : -2.571M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.571M |
| March 31, 2026 | -3.556M |
| December 31, 2025 | -2.768M |
| September 30, 2025 | -3.729M |
| June 30, 2025 | -1.734M |
| March 31, 2025 | -1.946M |
| December 31, 2024 | -3.564M |
| September 30, 2024 | 0.6618M |
| June 30, 2024 | -1.968M |
| March 31, 2024 | -3.117M |
| December 31, 2023 | -3.504M |
| September 30, 2023 | -2.691M |
| June 30, 2023 | -2.239M |
| March 31, 2023 | -2.192M |
| December 31, 2022 | -5.478M |
| September 30, 2022 | -9.856M |
| June 30, 2022 | -7.923M |
| March 31, 2022 | -0.9509M |
| Date | Value |
|---|---|
| December 31, 2021 | -10.04M |
| September 30, 2021 | -17.20M |
| June 30, 2021 | -0.9576M |
| March 31, 2021 | -0.9117M |
| December 31, 2020 | 0.0183M |
| September 30, 2020 | 1.550M |
| June 30, 2020 | -0.7065M |
| March 31, 2020 | 1.793M |
| December 31, 2019 | -1.319M |
| September 30, 2019 | 0.4897M |
| June 30, 2019 | 0.4189M |
| March 31, 2019 | 0.7759M |
| December 31, 2018 | -0.4758M |
| September 30, 2018 | -0.2932M |
| June 30, 2018 | -0.3264M |
| March 31, 2018 | -0.1148M |
| December 31, 2017 | -0.0262M |
| September 30, 2017 | -0.005M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.164M |
| Total Expenses (Quarterly) | 3.735M |
| EPS Diluted (Quarterly) | -0.1972 |
| Enterprise Value | 6.826M |
| Gross Profit Margin (Quarterly) | 99.44% |
| Profit Margin (Quarterly) | -220.8% |
| Earnings Yield | -586.5% |
| Normalized Earnings Yield | -586.52 |